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Abstract
Background: Carbapenem-resistant Acinetobacter baumannii has recently been defined by the World Health Organization
as a critical pathogen. The aim of this study was to compare clonal diversity and carbapenemase-encoding genes
of A. baumannii isolates collected from colonized or infected patients and hospital environment in two intensive
care units (ICUs) in Morocco.
Methods: The patient and environmental sampling was carried out in the medical and surgical ICUs of Mohammed V
Military teaching hospital from March to August 2015. All A. baumannii isolates recovered from clinical and environmental
samples, were identified using routine microbiological techniques and Matrix-Assisted Laser Desorption/Ionization
Time-of-Flight Mass Spectrometry. Antimicrobial susceptibility testing was performed using disc diffusion method.
The carbapenemase-encoding genes were screened for by PCR. Clonal relatedness was analyzed by digestion of
the DNA with low frequency restriction enzymes and pulsed field gel electrophoresis (PFGE) and the multi locus
sequence typing (MLST) was performed on two selected isolates from two major pulsotypes.
Results: A total of 83 multidrug-resistant A. baumannii isolates were collected: 47 clinical isolates and 36
environmental isolates. All isolates were positive for the blaOXA51-like and blaOXA23-like genes. The coexistence of
blaNDM-1/blaOXA-23-like and blaOXA 24-like/blaOXA-23-like were detected in 27 (32.5%) and 2 (2.4%) of A. baumannii
isolates, respectively. The environmental samples and the fecally-colonized patients were significantly identified
(p < 0.05) as the most common sites of isolation of NDM-1-harboring isolates. PFGE grouped all isolates into 9
distinct clusters with two major groups (0007 and 0008) containing up to 59% of the isolates. The pulsotype 0008
corresponds to sequence type (ST) 195 while pulsotype 0007 corresponds to ST 1089.The genetic similarity between
the clinical and environmental isolates was observed in 80/83 = 96.4% of all isolates, belonging to 7 pulsotypes.
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Conclusion: This study shows that the clonal spread of environmental A. baumannii isolates is related to that of clinical
isolates recovered from colonized or infected patients, being both associated with a high prevalence of the blaOXA23-like
and blaNDM-1genes. These findings emphasize the need for prioritizing the bio-cleaning of the hospital environment to
control and prevent the dissemination of A. baumannii clonal lineages.
Keywords: Acinetobacter Baumannii, Multidrug-resistant, Pulsed-field gel electrophoresis, OXA genes, blaNDM-1 gene,
Intensive care unit
Background
Multidrug-resistant (MDR) Acinetobacter baumannii is
recognized to be responsible for nosocomial outbreaks
in severely ill patients and it is predominantly isolated in
intensive care units (ICUs) around the world [1]. This
microorganism colonizes certain areas of the body such
as the skin, the oropharynx and the gastrointestinal tract
[1]. The prevalence of digestive tract colonization varies
from 8.3 to 41% in ICU patients [2, 3] but this pathogen
is also the causative agent of serious infections including
pneumonia, septicemia, urinary tract infection, wound
infection and meningitis with mortality rates varying from
7.8 to 75% [1]. Risk factors for Acinetobacter colonization
and infection are linked to the presence of underlying dis-
ease, long-term hospitalization, ICU stay, administration
of broad spectrum antibiotics and invasive procedures
such as mechanical ventilation or catheters [1, 4]. This
bacterium displays an outstanding ability to survive in the
environment, with some studies reporting up to 48% of
environmental samples being contaminated with Acine-
tobacter [5, 6]. Environmental sites most likely to be
contaminated include bed sheets, bed railings, touch
pads of ventilator equipment, trolleys, surfaces of re-
spiratory monitors as well as the hands and uniforms of
healthcare workers [5–7].
A. baumannii has also the capacity to develop resistance
to multiple antibiotics, which limits the therapeutic op-
tions to treat these infections [1, 4]. A recent Moroccan
study showed that the resistance rate of Acinetobacter
isolates to ciprofloxacin, imipenem, amikacin netilmicin,
and colistin was 87%, 86%, 52%, 33% and 1.7%,respectively
[8]. Resistance to carbapenems among A. baumannii
isolates all over the world is mostly linked to the carriage
of the blaOXA-23-like, blaOXA-24-like, and blaOXA-58-like genes,
encoding carbapenem hydrolyzing class D β-lactamases
(OXA-type), but also to the recent dissemination of the
blaNDM gene, encoding a class B metallo-β-lactamase
[9–14]. Since 2010, NDM-producing A. baumannii
isolates have been found in different countries includ-
ing Kenya, Ethiopia, Algeria, Egypt, Germany, France,
Spain, Turkey, India,Vietnam, China and Nepal [14, 15].
Overall, the clonal dissemination of carbapenem-resistant
A. baumannii isolates has been documented in different
countries [6, 7, 9–11] but only a few studies have focused
on the clonal relationships between clinical and environ-
mental isolates [5, 16, 17].
To our knowledge, there are no previous studies regard-
ing the prevalence of carbapenemase encoding genes or
the clonal diversity of A. baumannii isolates in Morocco.
The objective of this study was to characterize the
carbapenemase-encoding genes and molecular diversity of
clinical and environmental carbapenem-resistant A.
baumannii isolates recovered from two ICUs of a
Moroccan hospital.
Methods
This study was carried out in the clinical bacteriology
laboratory of Mohammed V Military teaching hospital in
collaboration with Barcelona Institute for Global Health
(IS global)-Hospital Clínic, Universitat de Barcelona.
Sampling strategies
The patient and environmental sampling was carried out
from March to August 2015 in the medical and surgical
ICUs of Mohammed V Military teaching hospital, a teaching
hospital with 700-beds, located in Rabat in the Kingdom of
Morocco, and which contains 2 ICUs (medical and surgical)
with 10 beds each, a center for burns, surgical and medical
units, and laboratory and imagery departments.
The clinical isolates were recovered from the mouth,
the anal margin and the groin for colonized patients and
from the respiratory tract and blood cultures for infected
patients. The criteria of colonization or infection were
assessed according to the Centers for Disease Control
and Prevention guidelines [18]. Screening samples were
collected at the time of ICU admission and weekly during
hospitalization. Collected clinical data included demo-
graphic characteristics, hospital wards, underlying diseases,
invasive procedures, specimen types, antibiotic use, ICU
length of stay and clinical outcome.
Environmental samples were collected from the patients’
rooms. At each site, an area of 10 cm2 was sampled using a
sterile swab moistened with physiological saline [19, 20].
The sampled sites were: floors, bed sheets, medical ven-
tilators, pillows, monitors, patient trolleys and intraven-
ous solution stand.
All swabs were then immersed in brain heart infusion
broth, incubated overnight at 37 °C and further subcultured
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on bromocresol purple lactose agar for the isolation of
Acinetobacter.
All Acinetobacter spp. isolates were identified using
routine microbiological techniques (direct examination,
biochemical test of orientation, API20NE) and species
identification was confirmed by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF-MS) [21].
Antibiotic susceptibility testing
Antimicrobial susceptibility testing was performed by
the disc diffusion method on Mueller-Hinton agar plates
in accordance with the French Society of Microbiology
in their 2015 recommendations guidelines. MDR A.
baumannii isolates were defined as resistant to three or
more classes of antibiotics represented by piperacillin/
tazobactam,ceftazidime, imipenem, ciprofloxacin, ami-
noglycosides and colistin [22].
PCR assays for detection of carbapenemase-encoding genes
DNA extractions from overnight cultures were performed
using PureLink® Genomic DNA Kit (Invitrogen, Carlsbad,
USA) and DNA IQ™ System (Promega Corporation,
Madison, WI, USA) according to the manufacturer’s in-
structions. PCR analysis was carried out as described
previously [23, 24] using the thermocycler (Biometra,
Göttingen, Germany) with the primers listed in Table 1.
Multiplex PCR assays were used to detect four
carbapenemase-encoding genes (blaOXA-51-like, blaOXA-23-like,
blaOXA-24-like and blaOXA-58-like). PCR amplifications for
blaOXA genes were performed in a final volume of 50 μl,
reaction mixtures contained 5 μl of 10× PCR buffer,
25 mmol/μL of MgCI2, 2.5 Mm of deoxynucleoside triphos-
phates (dNTPs), 0.5 μl of each primer, 1 U Taq DNA poly-
merase (New England BioLabs Inc., Beverly, MA, USA) and
3 μl of DNA template. The amplification conditions were
initial denaturation at 94 °C for 5 min, followed by 30 cycles
of 94 °C for 25 s, 52 °C for 40s and 72 °C for 50s, with final
extension for 6 min at 72 °C.
Uniplex PCR was used for detection of NDM-1 gene.
PCR reaction for blaNDM-1 gene was carried out by adding
0.5 μl of each primer, 5 μl of 10Xbuffer, 3 μl of MgCl2,
1.25 μl of dNTP’s, and 0.25 μl of Taq polymerase in a final
volume of 50 μl. PCR conditions were as follows: initial
denaturation at 94 °C for 10 min, followed by 32 cycles
consisting of denaturation at 94 °C for 30 s, 40 s annealing
at 57 °C, 50 s extension at 72 °C, followed by a final exten-
sion step at 72 °C for 5 min.
Hyperladder 100 bp (Bioline, London, UK) was used
as a molecular weight marker. PCR amplification prod-
ucts were analyzed by gel electrophoresis in a 1.5% w/v
Agarose gel stained with SYBR safe.
Molecular typing using pulsed-field gel electrophoresis
The clonal relationship of all isolates was analyzed by
PFGE as previously described with minor modifications
[25]. An overnight culture on blood agar was suspended
in 120 μl of cell suspension buffer (100 mM Tris-HCl,
100 mM EDTA, pH 8.0) and then, the bacterial suspen-
sion was mixed with an equal volume of 2% InCert™
Agarose (Lonza,Rockland,ME,USA) and dispensed in a
plug mould. Genomic DNA in agarose plugs was lysed
in the cell lysis solution (50 Mm Tris-HCl, 1% sarcosil,
100 μg/ml proteinase K), washed and digested with ApaI
(New England BioLabs Inc., Beverly, MA, USA). Electro-
phoresis was performed in 1% InCert™ Agarose (Lonza,
Rockland,ME,USA) and 0.5X TBE Buffer (PH 8.0) con-
taining 0.02 g of thiourea using either a CHEF-DR III
system (Bio-Rad Laboratories) or a CHEF-Mapper TM
apparatus (Bio-Rad Laboratories) at 6 V/cm2 with switch
times ranging from 5 s to 35 s at an angle of 120°, at
temperature of 14 °C, for 20 h.
A standard molecular weight Lambda DNA ladder
(Bio-Rad Laboratories) was included at least twice per
gel to allow normalization of all fingerprints. The Info-
Quest™FP v.4.5 software (Bio-Rad Laboratories) was used
for dendrogram construction by the UPGMA (Unweighted
Pair Group Method with Arithmetic Mean) method, based
on Dice’s similarity coefficient. Isolates were considered to
belong to the same PFGE cluster (pulsotype) if their Dice
similarity index was ≥ 85% [26].
On the basis of the number of isolates, PFGE pulso-
types were divided into major pulsotypes (more than ten
isolates/PFGE types), intermediate pulsotypes (five to
nine isolates/PFGE types) and minor pulsotypes (less
than five isolates/PFGE types) (Table 2).
Multi locus sequence typing (MLST)
The whole-genome sequencing was performed on the
extracted genomic DNA of the two selected strains of
major pulsotypes by using the Nextera XT DNA library
preparation kit (Illumina), with dual indexing adapters,
and sequenced using an Illumina MiSeq sequencer with
Table 1 Primers used for amplification of carbapenemase
genes [23, 24]
Primer Sequence (5′→3′) Amplicon size (bp)
OXA-51 F: TAATGCTTTGATCGGCCTTG
R: TGGATTGCACTTCATCTTGG
353
OXA-23 F: GATCGGATTGGAGAACCAGA
R: ATTTCTGACCGCATTTCCA
501
OXA-24 F: GGTTAGTTGGCCCCCTTAAA
R: AGTTGAGCGAAAAGGGGATT
246
OXA-58 F: AAGTATTGGGGCTTGTGCTG
R: CCCCTCTGCGCTCTACATAC
599
NDM-1 F:CATTTGCGGGGTTTTTAATG
R:CTGGGTCGAGGTCAGGATAG
998
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a 2 × 251-bp paired-end configuration. The Next Gener-
ation Sequencing Data (FASTA format) were then used
for further MLST analysis, carried out using MLST
Oxford scheme (https://pubmlst.org/abaumannii/).
Statistical analysis
Statistical analysis was performed using SPSS Statistics
for Windows, version 10.0. The results were expressed
as effective and percentages for qualitative variables and
as mean (standard deviation) or median (interquartile
range: IQR) for quantitative variables. The chi-square and
Fisher exact tests were used to compare the qualitative
variables. A comparison between the two quantitative var-
iables was performed using the Mann–Whitney U test for
non-normal distributed variables, whereas Student’s t-test
was used for normally distributed variables. P values less
than 0.05 were considered significant.
Results
Bacterial isolates and epidemiological data
A total of 83 non-duplicate A. baumannii isolates were
collected: 47 clinical isolates from 40 colonized or in-
fected patients and 36 isolates from 72 environmental
specimens.
Among 40 patients, 32 (80%) were colonized and 8
(20%) were infected. The epidemiological and clinical
characteristics of patients are shown in Table 3. The
average age was 54.38 ± 15.22 years and 30 (75%) were
males representing a sex ratio M/F of 3:1. The crude
mortality rate was 54.2%. The crude mortality rate was
43.8% in colonized patients and 87.5% in infected ones
(p = 0.031). Clinical isolates were recovered from 39
screening samples including anal margin (22/47 = 46.8%),
mouth (10/47 = 21.3%), groin (7/47 = 14.9%) and from 8
diagnosis samples composed of blood culture (3/
47 = 6.4%), protected distal sampling (3/47 = 6.4%) and
bronchial aspiration (2/47 = 4.2%).
Of the 72 environmental samples, 36 (50%) yielded A.
baumannii isolates. Surgical ICU samples were more
contaminated (22/31 = 71%) than those from the med-
ical ICU (14/41 = 34.1%) (p = 0.004). The environmental
A. baumannii isolates were obtained from bed sheets
(14/36 = 38.9%), floors (13/36 = 36.1%), medical ventila-
tors (4/36 = 11.1%), patient trolleys (2/36 = 5.5%), pillows
(1/36 = 2.8%), monitors (1/36 = 2.8%), and intravenous
solution stands (1/36 = 2.8%).
Antimicrobial susceptibility profile
All isolates were MDR. The difference in resistance rates
between the clinical isolates and the environmental ones
was not statistically significant except for gentamicin
(85.1% vs 100% respectively, p = 0.015).
Distribution of carbapenemase genes
The intrinsic chromosomally encoded blaOXA-51 like gene
characteristic of A. baumannii was detected in all isolates.
All isolates were positive for blaOXA-23-like.The coexistence
of blaNDM-1 with blaOXA-23-like and blaOXA 24-like with
blaOXA-23 was detected in 27 (32.5%) and 2 (2.4%) of A.
baumannii isolates, respectively. The blaOXA-58-like gene
was not detected. The percentage of NDM-1 carriage was
significantly higher in environmental isolates than in clin-
ical ones (18/36 = 50% vs 9/47 = 19.1%, p = 0.004). NDM-1
producing clinical isolates were recovered from: anal
margin (88.9%) and mouth (11.1%). The NDM-1 harboring
isolates were significantly (p = 0.006) more frequently iso-
lated from anal margin samples than from other clinical
specimens. The distribution of NDM-1 positive isolates
among hospital environment samples is as follows: bed
sheets (38.9%), floor (16.7%), medical ventilators (16.7%),
intravenous solution stands (5.5%), monitors (5.5%), patient
trolleys (5.5%) and pillows (5.5%). No significant differences
(p = 0.432) in the number of NDM-1 positive isolates were
found between different environmental sampling sites.
PFGE and MLST analyses
The isolates were classified into 9 PFGE pulsotypes
(0001–0009) with two major pulsotypes (0008, 0007),
Table 2 Distribution of PFGE pulsotypes according to the source of samples and status of pulsotypes
PFGE pulsotype Clinical isolates (N = 47) Environmental isolates (N = 36) Total (N = 83) Status of pulsotypes
N (%) N (%) N (%)
0001 7(14.9) 1(2.8) 8(9.6) Intermediate pulsotype
0002 1(2.1) 2(5.6) 3(3.6) Minor pulsotype
0003 1(2.1) 4(11.1) 5(6) Intermediate pulsotype
0004 2(2.4) 0 2(4.3) Minor pulsotype
0005 3(6.4) 4(11.1) 7(8.4) Intermediate pulsotype
0006 1(2.1) 0 1(1.2) Minor pulsotype (Singleton)
0007 16(34) 3(8.3) 19(22.9) Major pulsotype
0008 14(29.8) 16(44.4) 30(36.1) Major pulsotype
0009 2(4.3) 6(16.7) 8(9.6) Intermediate pulsotype
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containing up to 59% of all isolates. The strains of pulso-
type 0008 belonged to sequence type (ST) 195 while
those of pulsotype 0007 belonged to ST 1089. Clinical
isolates were found in all 9 different pulsotypes while
environmental isolates were only present in 7 pulso-
types, as they were missing from pulsotypes 0004 and
0006 which included just 2 and 1 isolates, respectively
(Table 2) (Fig. 1) (Additional file 1) .
Discussion
In the present study we have analyzed the clonal related-
ness and resistance characteristics of A. baumannii isolates
recovered. The clinical isolates were commonly isolated
from the anal margin (46.8%) followed by the mouth (24%).
The digestive tract of patients hospitalized in the ICU, has
been identified as an important site for Acinetobacter
colonization which can lead to severe infections, with a
prevalence of 8.3% in Saudi Arabia [2] and 41% in Spain
[3]. A study conducted in Spain by Corbella et al. showed
that MDR A. baumannii infections occurred more fre-
quently in patients with fecal colonization than in those
without fecal colonization [3]. The crude mortality found in
this study (50%) was comparable to that reported in colo-
nized or infected patients in Italy (58%) [27] but signifi-
cantly higher than that of Spanish hospitals (18.9%) [4].The
mortality rate of patients depends on clinical significance of
A. baumannii. In the current study, the mortality rate was
significantly higher in infected patients than in colonized
ones (87.5% vs 43.8%, p = 0. 031). This result is similar to
that of Rodríguez-Baño J et al. in Spain who showed that
crude mortality was higher in infected (27%) than in colo-
nized patients (10%) [4].
Our findings show a higher environmental contamin-
ation around infected or colonized patients in our ICU.
The presence of A. baumannii among environmental
specimens (50%) was higher than that observed in simi-
lar studies: 7.7% in Algeria [7], 9.9% in the United States
of America [19], 13.1% in China [16] and between 2%
and 18% in two different studies in Turkey [5, 6]. This
can be attributed to the lack of hospital decontamination
procedures and hand hygiene in our region. This study
also shows that the surgical ICU samples were more
contaminated than those of medical ICU (71% vs 37.2%,
p = 0.004) and the sites frequently touched by both the
health-care workers and patients were the most contam-
inated as the majority of environmental isolates were
recovered from floors (42.1%) followed by bed sheets
(34.2%) and medical ventilators (10.5%). These findings
are in agreement with that of other researchers who re-
ported that this pathogen was isolated from near-patient
surfaces, medical equipment, airborne samples and
healthcare workers’ hands [5–7, 19].
In the current study, all isolates were resistant to imi-
pinem. Carbapenem-resistance among A. baumannii
isolates has shown a steady increase in our region since
2001, when it was reported around 23.6% [28] and then
increased to 76.19% in 2012–2014 [8]. This can be ex-
plained by the excessive use of inadequate empirical
Table 3 Epidemiological and clinical features of colonized or
infected patients
Variable Total
N = 40
Number of Male patients(%) 30(75)
Mean Age (years) (Mean ± Standard deviation) 52.45 ± 16.5
Median length of ICU stay (days) [IQR] 10 [5–16]
Patients with lenght of ICU stay ≥7 days (%) 26(65)
Median duration of ICU stay prior to Colonization/
infection(days) [IQR]
6[1.5–16.5]
Respiratory distress 7(17.5)
postoperative care 10(25)
Cerebrovascular accidents 13(32.5)
Severe polytrauma 6(15)
Underlyning disease N (%)
Diabetes 7(17.5)
Chronic renal failure 5(12.5)
Arterial hypertension 6(15)
Chronic heart failure 7(17.5)
Chronic obstructive pulmonary disease 6(15)
Chronic smoking 6(15)
Solid tumor 7(17.5)
Invasive procedure N (%)
Venous catheter 11(27.5)
Arterial catheter 4(10)
Urinary catheter 26(65)
Mechanical ventilation 24(60)
Nasogastric tube 3(7.5)
Abdominal drain 4(10)
Recent surgery 4(10)
Parenteral nutrition 30(77.5)
Dialysis 3(7.5)
Septic shock N (%) 14(76)
Previous antibiotic treatment N (%) 35(87.5)
Amoxicillin/clavulanic acid N (%) 10(25)
Ceftriaxone N (%) 7(17.5)
Imipenem N (%) 23(57.5)
Aminoglycosides N (%) 19(47.5)
Colistin 9(22.5)
Ciprofloxacin 3(7.5)
Corticosteroid therapy N (%) 19(47.5)
Death rate N (%) 21(52.5)
ICU Intensive care unit, IQR Interquartile rang
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antimicrobial treatment including carbapenems, poor in-
fection control practices, poor antimicrobial stewardship
governance and widespread dissemination of carbapenem-
resistant strains in the community.
In the present study, carbapenem-resistance was mainly
attributed to the carriage of the blaOXA-23-like gene that was
present in all isolates (100%).This prevalence is similar to
that reported in Turkey (100%) [11] and Egypt (100%) [12]
but higher than that observed in Brazil (95.4%) [29], Asian
pacific countries (95%) [9], France (82%) [30], South Africa
(77%) [31] and Italy (71.7%) [10]. During the past decades,
outbreak or sporadic A. baumannii clones producing OXA-
Fig. 1 PFGE dendrogram of Clinical and environmental A.baumannii isolates (M-ICU: Medical intensive care unit, S-ICU: Surgical intensive care unit)
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23 have disseminated around the world [32] but such
dissemination has been particularly relevant among
Mediterranean countries, where the blaOXA-23-like gene
has replaced previously predominant blaOXA genes
such as blaOXA-24-like and blaOXA-58-like [33]. In our study,
only 2 clinical isolates also harbored the blaOXA-24-like gene
(4.25%) but this gene was not detected among the envir-
onmental isolates and all isolates were negative for the
blaOXA-58-like gene. The high prevalence of blaOXA-23-like
gene is probably associated with horizontal gene transfer
by mobile genetic elements such as plasmids, transposable
elements and integron systems. It has been reported that
the spread of blaOXA-23-like genes is associated with the
Tn2006, Tn2007, Tn2008, and Tn2009 transposons, which
can be further located on the chromosome or on conjuga-
tive plasmids [32, 34, 35].
Likewise, 32.5% of all isolates also presented the blaNDM-1
gene and this is the first time that NDM-producing A. bau-
mannii isolates are reported in Morocco. Our results indi-
cate that NDM-1-producing A. baumannii isolates are
widely circulating in the hospital environment and they
were found in all environmental sampling sites. Moreover,
the NDM-1-producing A. baumannii isolates were more
frequently recovered (p = 0.004) from environmental
isolates (50%) than from clinical isolates (19.1%).The
environmental NDM-1 producing A. baumannii iso-
lates have also been reported in Algeria [7] and in
China [36]. The high rate of environmental blaNDM-1
contamination is alarming as the hospital environment
may become a potential reservoir for A. baumannii
isolates carrying NDM-1 which could result in transfer
the blaNDM-1 gene to other bacterial species.
Among clinical isolates, the anal margin samples were
identified (p = 0.006) as the most common sites of isola-
tion of NDM-1-producing A. baumannii isolates. These
findings also highlight the role played by fecally-colonized
patients as reservoirs for carbapenem-resistant nosoco-
mial A. baumannii isolates.
In the current study, the genetic similarity between
clinical and environmental isolates was observed in (80/
83 = 96.4%) of all isolates, classified into 7 pulsotypes
(0001, 0002, 0003, 0005, 0007, 0008 and 0009). These
results suggest a dynamic exchange of A. baumannii
isolates between patients and their environmental sur-
roundings. These pathogens can be transmitted from
patient-to-patient, patient to a health care worker, pa-
tient to environment and vice versa. In our study, three
clinical isolates belonging to the pulsotypes (0004 and
0006) which were not detected in environmental iso-
lates, may be exclusively transmitted through direct
contact between an infected or colonized patient and
another person or they may come from other environ-
mental reservoirs which are either rare or not identified
in our study.
Our results also show that the most frequent pulso-
type was PFGE type 0008 (30/83 = 36.1%). Among the
two major pulsotypes, clinical isolates were predominant
within pulsotype 0007 (16/47 = 34%) while environmental
isolates were a majority within pulsotype 0008 (16/
36 = 44.4%). Overall, however, both major pulsotypes were
closely related (Dice similarity >82%) and contained up to
59% of all isolates, they were found in all sampling sites
and it is clear that they have become endemic in this
particular setting. The PFGE cluster 0008 corresponds to
ST195 (Oxford MLST) which has been previously re-
ported from Asian countries, European nations and Egypt
[37–39] while the strains from pulsotype 0007 were
assigned to ST 1089(Oxford MLST) which is very rare ST
and according to “the profile history for A. baumannii
MLST (Oxford) database”, the ST 1089 has been found
for the first time in India in 2015.
Conclusion
This study shows that the clonal spread of environmental
A. baumannii isolates is related to that of clinical isolates
recovered from colonized or infected patients. Our results
have also shown that OXA-23 is the most common carba-
penemase among A. baumannii isolates in our hospital
but the prevalence of isolates producing both OXA-23
and NDM-1 is also alarming.
Effective control measures are urgently needed to pre-
vent the transmission of endemic lineages of MDR A.
baumannii and they should take into account the decon-
tamination of the patients’ environmental surroundings.
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